Show simple item record

dc.contributor.authorTuffaha, H
dc.contributor.authorScuffham, P
dc.date.accessioned2020-04-17T01:04:44Z
dc.date.available2020-04-17T01:04:44Z
dc.date.issued2019
dc.identifier.issn1098-3015
dc.identifier.doi10.1016/j.jval.2019.09.292
dc.identifier.urihttp://hdl.handle.net/10072/393168
dc.description.abstractGenetic testing for a germline BRCA mutation in women with HER2-negative metastatic breast cancer (MBC) can guide targeted treatment with PARP inhibitors (e.g. olaparib) and inform cancer prevention strategies (e.g., risk-reducing surgery) for family members of women who test positive. Unlike BRCA testing in localised breast cancer, the cost-effectiveness of genetic testing in MBC is unknown. This study aimed to evaluate the cost-effectiveness of BRCA testing in women with MBC to guide olaparib treatment.
dc.languageEnglish
dc.publisherElsevier
dc.relation.ispartofconferencenameISPOR Europe 2019
dc.relation.ispartofconferencetitleVALUE IN HEALTH
dc.relation.ispartofdatefrom2019-11-02
dc.relation.ispartofdateto2019-11-06
dc.relation.ispartoflocationCopenhagen, Denmark
dc.relation.ispartofpagefromS454
dc.relation.ispartofpagetoS454
dc.relation.ispartofissueSupplement 3
dc.relation.ispartofvolume22
dc.relation.urihttp://purl.org/au-research/grants/NHMRC/APP1121232
dc.relation.grantIDAPP1121232
dc.relation.fundersNHMRC
dc.subject.fieldofresearchPublic Health and Health Services
dc.subject.fieldofresearchApplied Economics
dc.subject.fieldofresearchcode1117
dc.subject.fieldofresearchcode1402
dc.subject.keywordsSocial Sciences
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsEconomics
dc.subject.keywordsHealth Care Sciences & Services
dc.titleCost-effectiveness analysis of germline brca mutation testing and olaparib treatment in metastatic breast cancer: An evaluation of codependent technologies
dc.typeConference output
dc.type.descriptionE3 - Conferences (Extract Paper)
dcterms.bibliographicCitationTuffaha, H; Scuffham, P, Cost-effectiveness analysis of germline brca mutation testing and olaparib treatment in metastatic breast cancer: An evaluation of codependent technologies, Value in Health, 2019, 22, pp. S454-S454
dc.date.updated2020-04-17T00:57:11Z
gro.hasfulltextNo Full Text
gro.griffith.authorTuffaha, Haitham W.
gro.griffith.authorScuffham, Paul A.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Conference outputs
    Contains papers delivered by Griffith authors at national and international conferences.

Show simple item record